Lixte Biotechnology Holdings Inc. (LIXT) shares rose 13.76 percent to $3.39 in pre-market trade Thursday. The market price of Lixte stock ended last trading day at $2.96, down -6.92%. Trading volume for LIXT stock was 62899 shares, less than the average daily trading volume of 0.25 million shares over the past 50 days.

While they have retreated -1.33% over the last five days, shares of LIXT have lost -1.00% in the past month. This year, LIXT has lost -48.88 percent so far and has lost -0.34% over the last three months. In response to outside research on its cancer treatment compound, LIXT stock rose.

What research has been done?

In addition to developing drugs for many types of cancer, Lixte Biotechnology is tackling more serious common diseases through research. One of the major causes of cancer is the malfunctioning of the switches that turn the biochemical pathways “on” and “off” in cells.

During the past 30 years, cancer research has largely focused on “on” switches since “off” switches, especially the protein phosphatase (PP2A) master “off” switch, caused unacceptably high toxicities in patients. LB-100, LIXT’s novel, first-in-class lead compound, was found to be well tolerated in cancer patients at doses associated with anti-cancer activity, demonstrating that it has the potential to prevent the development of cancer.

On Tuesday, Lixte announced that National Latino Leader Award winner Julio Pimentel from Wayne State University School of Medicine’s Cancer Biology program had been chosen for the second time to receive a scholarship and the award.

• The Society of Advancing Chicanos/Hispanics and Native Americans in the Sciences Conference, taking place October 25-29, 2021, will be the perfect venue for Pimentel where he will present virtually studies of LB-100 in triple negative breast cancer (TNBC).
• The award acknowledges his considerable achievements in research despite the challenges caused by COVID 19.
• Pimentel and his coauthors were congratulated by LIXT for demonstrating that LB-100 inhibits TNBC cell growth, whether the cells are resistant to TRAIL or not.
• LIXT’s LB-100 sensitizes TNBC cells to chemotherapy drugs like paclitaxel and cisplatin, which are used regularly for treating TNBC.
• Researchers Pimentel and his colleagues concluded that inhibition of PP2A activity has therapeutic potential in treating this notoriously unresponsive type of breast cancer.

The LB-100 strategy of LIXT:

Many preclinical studies have shown that LB-100 can enhance conventional therapy for many types of cancer, including some of the most aggressive kinds. A good example of this is the report from Wayne State University. Lixte (LIXT) is evaluating LB-100 as a component of chemotherapy for TNBC, and is seeking a partner interested in conducting studies on LB-100 there.